News - Oncology, Patents


Current filters:


Popular Filters

1 to 25 of 46 results

Novartis patent settlement on Gleevec with Sun Pharma subsidiary


The US unit of Swiss drug major Novartis has settled its litigation with the US subsidiary of India’s…

GenericsGleevecNovartisOncologyPatentsSun Pharmaceutical IndustriesUSA

Lilly's Alimta patent upheld through 2022

Lilly's Alimta patent upheld through 2022


US pharma major Eli Lilly says that the US District Court for the Southern District of Indiana has ruled…

AlimtaEli LillyLegalNorth AmericaOncologyPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP

Roche sues Biocon and Mylan over Herceptin biosimilar; US puts pressure on India over IP


Swiss pharma major Roche’s Indian subsidiary has sued Bangalore-based Biocon and US generics firm Mylan…

Asia-PacificBioconBiosimilarsCanmabHerceptinHertrazIndiaLegalMylan LaboratoriesOncologyPatentsPharmaceuticalRegulationRoche

Actavis confirms generic Treanda patent challenge

Actavis confirms generic Treanda patent challenge


US generics drug major Actavis confirms that it has filed an Abbreviated New Drug Application with the…

ActavisCephalonGenericsNorth AmericaOncologyPatentsTeva Pharmaceutical IndustriesTreandaUSA

Ukraine government introduces compulsory licensing for pharma products

Ukraine government introduces compulsory licensing for pharma products


Leading global pharmaceutical producers may suffer significant losses in Ukraine, as the country’s…

Anti-viralsAntibiotics and Infectious diseasesEastern EuropeLicensingOncologyPatentsPharmaceuticalUkraine

Another blow for Pharma, as India revokes Tykerb patent


UK pharma giant GlaxoSmithKline (LSE: GSK) has confirmed that India's Intellectual Property Appellate…


Mylan enters Tarceva settlement agreement


US generics firm Mylan (Nasdaq: MYL) has entered into a settlement agreement with OSI Pharmaceuticals,…

GenentechGenericsLegalMylan LaboratoriesNorth AmericaOncologyOSI PharmaceuticalsPatentsPfizerTarceva

US Court denies re-hearing of Arzerra patent case


Danish drugmaker Genmab (OMX: GEN) says that the US Court of Appeals for the Federal Circuit has declined…

ArzerraBiogen IdecBiotechnologyGenentechGenmabGlaxoSmithKlineLegalNorth AmericaOncologyPatentsPharmaceutical

Intas Pharma settles with Roche over Xeloda; Merck & Co wins injunction against Aprica


Indian drugmaker Intas Pharmaceuticals and its wholly owned subsidiary Accord Healthcare have entered…

Aprica PharmaceuticalsAsia-PacificDiabetesGenericsIntas PharmaceuticalsMerck & CoNorth AmericaOncologyPatentsRocheXeloda

CML drug revenue in Japan to grow, despite global decline, says GlobalData


Bucking a global trend of falling revenues, weak penetration of generic drugs and an increasing patient…

Asia-PacificBristol-Myers SquibbGleevecMarkets & MarketingNovartisOncologyPatentsPharmaceuticalSprycel

Cyclacel sells four disputed romidepsin-related patents to Celgene


USA based Cyclacel Pharmaceuticals (Nasdaq: CYCC) says that it has entered into a definitive agreement…

BiotechnologyCelgeneCyclacel PharmaceuticalsLegalOncologyPatentsromidepsin

India's Supreme Court denies Novartis Glivec patent appeal


In a landmark decision issued on Monday (April 1) by the Indian Supreme Court has denied Swiss drug major…


Indian patent appeal board upholds compulsory license on Bayer's Nexavar


After much delay, the verdict into German pharmaceutical major Bayer's (BAYN: DE) appeal against the…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal


The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating…

Asia-PacificCiplaCipla MedproGenericsLegalMergers & AcquisitionsOncologyPatentsPfizerRest of the WorldSutent

Zhejiang Hisun Pharma pulls out of ThermoDox deal with Celsion


US cancer drug developer Celsion Corp (Nasdaq: CLSN) says that Zhejiang Hisun Pharmaceutical (SSE: 600267)…

Asia-PacificCelsionLicensingOncologyPatentsPharmaceuticalThermoDoxZhejiang Hisun Pharma

Regulatory news for Hyperion's Ravicti and Seattle Genetics' Adcetris


The US Food and Drug Administration on Friday approved Hyperion Therapeutics' (Nasdaq: HPTX) Ravicti…

AdcetrisBiotechnologyHyperion TherapeuticsNorth AmericaOncologyPatentsPharmaceuticalRare diseasesRavictiRegulationSeattle Genetics

Indian govt plans compulsory licences for trastuzumab, ixabepilone and dasatinib


The Indian government's move to issue compulsory licences to three more patented cancer drugs has left…

Asia-PacificAvastinBristol-Myers SquibbGenericsIxempraOncologyPatentsPharmaceuticalRocheSprycel

1 to 25 of 46 results

Back to top